The resveratrol analogue 3,5,3′,4′,5′-pentahydroxy-trans- stilbene inhibits cell transformation via MEK

International Journal of Cancer

Volumn 123, Issue 11, 2008, Pages 2487-2496

  Ki, Won Lee ^a,b   Nam, Joo Kang ^a,c   Rogozin, Evgeny A ^a   Oh, Sang Muk ^a   Yong, Seok Heo ^b   Pugliese, Angelo ^a   Bode, Ann M ^a   Hyong, Joo Lee ^c   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Konkuk University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

AP 1; Cell transformation; MEK; Resveratrol analogue; RSVL2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3,5,3',4',5' PENTAHYDROXYSTILBENE; ADENOSINE TRIPHOSPHATE; AMIDE; HYDROXYL GROUP; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHORBOL 13 ACETATE 12 MYRISTATE; RAF PROTEIN; RESVERATROL; SERINE; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING KINETICS; CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; EPIDERMIS CELL; GENE EXPRESSION; HYDROGEN BOND; INHIBITION KINETICS; MOLECULAR MODEL; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN CONFORMATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-RAF; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; STILBENES; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION;

EID: 57349153022     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23830     Document Type: Article

References (33)

1. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
2. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20.
3. Bode AM, Dong Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 2000;1:181-8.
4. Dong Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res 2003;523-524:145-50.
5. Gosslau A, Chen M, Ho CT, Chen KY. A methoxy derivative of resveratrol analogue selectively induced activation of the mitochon-drial apoptotic pathway in transformed fibroblasts. Br J Cancer 2005;92:513-21.
6. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999;20:237-42.
7. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 2001;61:1604-10.
8. Lu J, Ho CH, Ghai G, Chen KY. Resveratrol analog, 3,4,5,40- tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis 2001;22:321-8.
9. She QB, Ma MY, Wang M, Kaji A, Ho CT, Dong Z. Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved. Oncogene 2003;22:2143-50.
10. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 1994;91:609-13.
11. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA 1997;94:5826-30.
12. Lee KW, Lee HJ. The roles of polyphenols in cancer chemoprevention. Biofactors 2006;26:105-21.
13. Huang C, Ma WY, Young MR, Colburn N, Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci USA 1998;95:156-61.
14. Suzukawa K, Weber TJ, Colburn NH. AP-1, NF-j-B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model. Environ Health Perspect 2002;110:865-70.
15. Anderson NG, Maller JL, Tonks NK, Sturgill TW. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990;343:651-3.
16. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-52.
17. Sebolt-Leopold JS, Dudley DT, Herrera R, Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-16.
18. Shapiro P. Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. Crit Rev Clin Lab Sci 2002;39:285-330.
19. Chung JY, Park JO, Phyu H, Dong Z, Yang CS. Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. FASEB J 2001;15:2022-4.
20. Chung JY, Huang C, Meng X, Dong Z, Yang CS. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 1999;59:4610-17.
21. Feng R, Lu Y, Bowman LL, Qian Y, Castranova V, Ding M. Inhibition of activator protein-1, NF-κB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem 2005;280:27888-95.
22. Ding M, Lu Y, Bowman L, Huang C, Leonard S, Wang L, Vallyathan V, Castranova V, Shi X. Inhibition of AP-1 and neoplastic transformation by fresh apple peel extract. J Biol Chem 2004;279:11670-6.
23. Bernstein LR, Colburn NH. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 1989;244:566-9.
24. Dong Z, Cmarik JL. Harvesting cells under anchorage-independent cell transformation conditions for biochemical analyses. Sci STKE 2002;2002:PL7.
25. Wang M, Jin Y, Ho CT. Evaluation of resveratrol derivatives as potential antioxidants and identification of a reaction product of resveratrol and 2, 2-diphenyl-1-picryhydrazyl radical. J Agric Food Chem 1999;47:3974-7.
26. Colburn NH, Wendel EJ, Abruzzo G. Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc Natl Acad Sci USA 1981;78:6912-16.
27. She QB, Huang C, Zhang Y, Dong Z. Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog 2002;33:244-50.
28. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-9.
29. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
30. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Dyk DEV, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, et al. Identification of a novel inhibitor of mitogen-activated protein kinase. J Biol Chem 1998;273:18623-32.
31. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, et al. Structures of human MAP kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192-7.
32. Bode AM, Dong Z. Signal transduction pathways in cancer development and as targets for cancer prevention. Prog Nucleic Acid Res Mol Biol 2005;79:237-97.
33. Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, Colburn NH. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 1998;17:3493-8.